Protein kinases--the major drug targets of the twenty-first century? - PubMed

Affiliations

• PMID: 12120282
• DOI: 10.1038/nrd773

Review

Protein kinases--the major drug targets of the twenty-first century?

Philip Cohen. Nat Rev Drug Discov. 2002 Apr.

Abstract

Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease. A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clinical use. Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors. Here, I give a personal view of some of the most important advances that have shaped this field.

Similar articles

• Protein kinase inhibitors as a therapeutic modality.

  Levitzki A. Levitzki A. Acc Chem Res. 2003 Jun;36(6):462-9. doi: 10.1021/ar0201207. Acc Chem Res. 2003. PMID: 12809533 Review.

• Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  Goldman JM, Melo JV. Goldman JM, et al. N Engl J Med. 2001 Apr 5;344(14):1084-6. doi: 10.1056/NEJM200104053441409. N Engl J Med. 2001. PMID: 11287980 No abstract available.

• [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].

  Molnár L, Losonczy H. Molnár L, et al. Orv Hetil. 2002 Oct 20;143(42):2379-84. Orv Hetil. 2002. PMID: 12440260 Review. Hungarian.

• Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.

  Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Force T, et al. Circulation. 2004 Mar 16;109(10):1196-205. doi: 10.1161/01.CIR.0000118538.21306.A9. Circulation. 2004. PMID: 15023894 Review.

• Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

  Druker BJ. Druker BJ. Oncogene. 2002 Dec 9;21(56):8541-6. doi: 10.1038/sj.onc.1206081. Oncogene. 2002. PMID: 12476300 Review. No abstract available.

Cited by

• A survey of the kinome pharmacopeia reveals multiple scaffolds and targets for the development of novel anthelmintics.

  Knox J, Joly N, Linossi EM, Carmona-Negrón JA, Jura N, Pintard L, Zuercher W, Roy PJ. Knox J, et al. Sci Rep. 2021 Apr 28;11(1):9161. doi: 10.1038/s41598-021-88150-6. Sci Rep. 2021. PMID: 33911106 Free PMC article.

• Phospholipid Ozonation Products Activate the 5-Lipoxygenase Pathway in Macrophages.

  Zemski Berry KA, Murphy RC. Zemski Berry KA, et al. Chem Res Toxicol. 2016 Aug 15;29(8):1355-64. doi: 10.1021/acs.chemrestox.6b00193. Epub 2016 Aug 3. Chem Res Toxicol. 2016. PMID: 27448436 Free PMC article.

• Chasing phosphohistidine, an elusive sibling in the phosphoamino acid family.

  Kee JM, Muir TW. Kee JM, et al. ACS Chem Biol. 2012 Jan 20;7(1):44-51. doi: 10.1021/cb200445w. Epub 2011 Dec 9. ACS Chem Biol. 2012. PMID: 22148577 Free PMC article. Review.

• Global Phosphoproteomic Analysis Reveals the Involvement of Phosphorylation in Aflatoxins Biosynthesis in the Pathogenic Fungus Aspergillus flavus.

  Ren S, Yang M, Li Y, Zhang F, Chen Z, Zhang J, Yang G, Yue Y, Li S, Ge F, Wang S. Ren S, et al. Sci Rep. 2016 Sep 26;6:34078. doi: 10.1038/srep34078. Sci Rep. 2016. PMID: 27667718 Free PMC article.

• Cell signaling, post-translational protein modifications and NMR spectroscopy.

  Theillet FX, Smet-Nocca C, Liokatis S, Thongwichian R, Kosten J, Yoon MK, Kriwacki RW, Landrieu I, Lippens G, Selenko P. Theillet FX, et al. J Biomol NMR. 2012 Nov;54(3):217-36. doi: 10.1007/s10858-012-9674-x. Epub 2012 Sep 26. J Biomol NMR. 2012. PMID: 23011410 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database